

Amendments to the Specification:

Please change the paragraph at page 17, lines 5-32, with the following:

Peptides particularly of interest for use in the present invention include laminin, which has the sequence

YIGSR

(SEQ ID NO: 7)

echistatin, which has the sequence

ECESGPCCRNCKFLKEGTICKRARGDDMDDYCNGKTCDCPRNPHKGPAT

(SEQ ID NO: 8)

RGD, NGR and derivatives thereof having the sequences

$RX_1ETX_2WX_3$

(SEQ ID NO: 9)

wherein X_1 , X_2 , and X_3 are any amino acid;

$CX_1X_2RLDX_3X_4C$

(SEQ ID NO: 11)

wherein X_1 , X_2 , X_3 and X_4 are any amino acid;

~~CXXRGDC~~

~~(SEQ ID NO: 12)~~

$X_1X_2X_3RGDX_4X_5X_6$

(SEQ ID NO: 13)

wherein X_1 , X_3 , X_4 , and X_6 are capable of forming a bridge (by disulfide bonds, peptide bonds or lactam bonds) and X_2 and X_5 are 1 to 5 amino acids;

$CX_2CRGDCX_5C$

(SEQ ID NO: 14)

wherein X_2 and X_5 are 1 to 5 amino acids;

~~$X_1X_2DDX_4X_5X_7X_8$~~

$X_1X_2DDX_5X_6X_7X_8$

(SEQ ID NOS: 15, 138-161)

wherein X_1 and X_8 each is an independently selected amino acid, X_2 and X_7 together equal 0 to 4 amino acids, each amino acid of which is independently selected, $[X_4]X_5$ is selected from the group consisting of glycine and leucine, and $[X_5]X_6$ is selected from the group consisting of tryptophan and leucine;



(SEQ ID NO: 16)

wherein X_1 and $[X_8]X_{10}$ each is an independently selected amino acid, X_2 and $[X_7]X_9$ together equal 0 to 3 amino acids, each amino acid of which is independently selected, X_3 is selected from the group consisting of tryptophan and proline, $[X_4]X_6$ is selected from the group consisting of glycine and leucine, $[X_5]X_7$ is selected from the group consisting of tryptophan and leucine, and $[X_6]X_8$ is selected from the group consisting of leucine, tryptophan, and methionine.

The substituents ~~$X_1, X_2, X_3, X_4, X_5, X_6, X_7$, and X_8~~ $X_1, X_2, X_3, X_6, X_7, X_8, X_9$, and X_{10} are as defined in International applications WO 95/14714, published June 1, 1995 and WO 97/08203, published March 6, 1997 (corresponding to U.S. Pat. Nos. 5,627,263 and 5,817,750, respectively), which are incorporated by reference in their entirety.

Appl. No. 09/840,277

Amdt. dated January ___, 2005

Reply to Office Action of November 24, 2004

Amendments to the Sequence Listing:

The attached sequence listing replaces the original sequence listing filed in this matter.